Diamyd axes diabetes and 70% of staff, and seeks solace in pain and neurology
This article was originally published in Scrip
Executive Summary
Following the catastrophic failure of its diabetes candidate, Diamyd Medical says it is now "concentrating its resources on the company's drug candidates for the treatment of pain and diseases of the nervous system" instead.